Pharmacological blood-pressure lowering for the prevention of cardiovascular disease and death across the full spectrum of chronic kidney disease severity: an individual-participant data meta-analysis

The authors aimed to investigate the effects of blood-pressure-lowering treatment on the risk of major cardiovascular events and mortality across various stages of chronic kidney disease (CKD). Their analysis of individual-participant data from 52 randomized controlled trials revealed that a reduction in systolic blood pressure similarly decreased cardiovascular risk in individuals with and without CKD, although the benefit was less pronounced in those with CKD and concurrent diabetes. The findings suggest that while blood-pressure management is effective across all CKD stages, tailored strategies may be necessary for patients with CKD and diabetes.